title: Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008).
abstract: OBJECTIVE
  To describe clinical characteristics, treatment, and outcome of dogs with inflammatory carcinoma (IC) and identify patient-, tumor-, and treatment-related factors associated with overall survival time.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  43 client-owned dogs.
  
  
  METHODS
  Records of dogs with a clinical diagnosis of IC that had histologic evidence of dermal lymphatic invasion were reviewed. Data on clinical staging, treatment, toxicoses, response, and survival time were retrieved. Results-26 (60%) dogs had primary IC and 17 (40%) had secondary IC. Thirty-five (81%) dogs had distant metastases and 2 (5%) had local metastases at the time of initial examination. Six of 29 (21%) dogs had a coagulopathy. Sixteen (37%) dogs did not receive specific treatment for IC, 24 (56%) received medical treatment only, 2 (5%) underwent surgical excision and received medical treatment, and 1 (2%) underwent surgical excision only. Forty-one (95%) dogs had progressive disease, and 2 (5%) had stable disease. Mean survival time for all dogs was 60 days (range, 1 to 300 days). Dogs with a coagulopathy survived a significantly shorter time than did dogs without a coagulopathy (odds ratio, 0.28), and dogs that received medical treatment survived significantly longer than dogs that did not (odds ratio, 2.54).
  
  
  CONCLUSIONS
  Results suggested that mammary IC is a biologically aggressive condition in dogs associated with a guarded prognosis. In addition, results suggested that medical treatment may improve outcome, thereby supporting its use in dogs with IC.
authors.affiliation: Clinica Veterinaria L'Arca, Vico Cacciottoli 46, 80129 Naples, Italy. lauramarconato@yahoo.it
authors.forename: Laura
authors.initials: L
authors.lastname: Marconato
authors.forename: Giorgio
authors.initials: G
authors.lastname: Romanelli
authors.forename: Damiano
authors.initials: D
authors.lastname: Stefanello
authors.forename: Claudio
authors.initials: C
authors.lastname: Giacoboni
authors.forename: Ugo
authors.initials: U
authors.lastname: Bonfanti
authors.forename: Giuliano
authors.initials: G
authors.lastname: Bettini
authors.forename: Riccardo
authors.initials: R
authors.lastname: Finotello
authors.forename: Sara
authors.initials: S
authors.lastname: Verganti
authors.forename: Paola
authors.initials: P
authors.lastname: Valenti
authors.forename: Luigia
authors.initials: L
authors.lastname: Ciaramella
authors.forename: Eric
authors.initials: E
authors.lastname: Zini
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000662:veterinary*; D004283:Dog Diseases / Q000473:pathology*; D004285:Dogs; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents